Future studies will be required to assess whether salbutamol could be of importance in the treatment of disease in which TRPV4 gain-of-function mutations can be present, such as SMA, Charcot–Marie–Tooth disease, and other pathologies. Here, TRPV4 is linked to proximal spinal muscular atrophy.